{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-028189","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.334758+00:00","generated_at":"2026-06-12T02:34:12.747868+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lyell Immunopharma Q2 net loss $63.9M, no revenue, cash $632.7M; Phase 1 data on track","bullets":["Net loss of $63.9M for Q2 2023, compared to $36.3M in Q2 2022; non-GAAP net loss $45.6M vs $10.3M.","Revenue near zero vs $35.7M in prior year period, due to termination of GSK collaboration in Dec 2022.","Cash, cash equivalents and marketable securities $632.7M as of June 30, 2023; expected to fund operations into 2026.","Appointed Matt Lang as Chief Business Officer, also serving as Chief Legal Officer and Corporate Secretary.","Phase 1 trials LYL797 and LYL845 ongoing; initial data expected 2024; IND for LYL119 expected H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-028189","json":"https://secwatch.observer/filing/0001628280-23-028189.json","markdown":"https://secwatch.observer/filing/0001628280-23-028189.md","text":"https://secwatch.observer/filing/0001628280-23-028189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023028189/0001628280-23-028189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023028189/lyel-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:34:12.747868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bc303036c518b3f65ddeae88594cd458707921a","claim":"Lyell Immunopharma, Inc. reported the quarter ended June 30, 2023 results: revenue approximately zero, net income net loss of $63.9 million.","evidence_excerpt":"Lyell reported a net loss of $63.9 million for the second quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023028189/0001628280-23-028189-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"approximately zero"},{"label":"Net income","value":"net loss of $63.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}